These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23508847)

  • 1. Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies.
    Hu L; Hansen RJ
    J Pharm Sci; 2013 Sep; 102(9):2898-908. PubMed ID: 23508847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
    Singh AP; Shin YG; Shah DK
    Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development?
    Deng R; Jin F; Prabhu S; Iyer S
    Expert Opin Drug Metab Toxicol; 2012 Feb; 8(2):141-60. PubMed ID: 22248267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically-based modeling of monoclonal antibody pharmacokinetics in drug discovery and development.
    Glassman PM; Balthasar JP
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):3-13. PubMed ID: 30522890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.
    Kamath AV
    Drug Discov Today Technol; 2016; 21-22():75-83. PubMed ID: 27978991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.
    Lansita JA; Mounho-Zamora B
    Curr Pain Headache Rep; 2015; 19(2):2. PubMed ID: 25681157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessments of antibody biodistribution.
    Glassman PM; Abuqayyas L; Balthasar JP
    J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S29-38. PubMed ID: 25707961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody pharmacokinetics and pharmacodynamics.
    Wang W; Wang EQ; Balthasar JP
    Clin Pharmacol Ther; 2008 Nov; 84(5):548-58. PubMed ID: 18784655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational strategies for development of monoclonal antibodies from discovery to the clinic.
    Tabrizi MA; Bornstein GG; Klakamp SL; Drake A; Knight R; Roskos L
    Drug Discov Today; 2009 Mar; 14(5-6):298-305. PubMed ID: 19152840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development.
    Mould DR; Green B
    BioDrugs; 2010 Feb; 24(1):23-39. PubMed ID: 20055530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.
    Zheng Y; Scheerens H; Davis JC; Deng R; Fischer SK; Woods C; Fielder PJ; Stefanich EG
    Clin Pharmacol Ther; 2011 Feb; 89(2):283-90. PubMed ID: 21191378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network biology in development of monoclonal antibody therapeutics.
    Ovacik AM
    Math Biosci; 2015 Feb; 260():6-10. PubMed ID: 25311982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
    Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development.
    Ovacik M; Lin K
    Clin Transl Sci; 2018 Nov; 11(6):540-552. PubMed ID: 29877608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.
    Samineni D; Girish S; Li C
    Expert Rev Clin Pharmacol; 2016 Dec; 9(12):1557-1569. PubMed ID: 27766899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody therapeutics: history and future.
    Buss NA; Henderson SJ; McFarlane M; Shenton JM; de Haan L
    Curr Opin Pharmacol; 2012 Oct; 12(5):615-22. PubMed ID: 22920732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development.
    Tibbitts J; Canter D; Graff R; Smith A; Khawli LA
    MAbs; 2016; 8(2):229-45. PubMed ID: 26636901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.
    Lee JW; Salimi-Moosavi H
    Bioanalysis; 2012 Oct; 4(20):2513-23. PubMed ID: 23157359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.